ADC Therapeutics SA
ADCT· NYSE
Released May 4, 2026, before the open
10-Q filed May 4, 2026, 34 days after period end · 0001628280-26-029819
| Metric | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 |
|---|---|---|---|---|
| Revenue | $20.03M | $17.40M | $17.85M | $18.95M |
| Net Income | -$32.97M | -$38.60M | -$46.61M | -$59.37M |
| EPS Diluted |
ADC Therapeutics SA · CIK 1771910 · Engraved from SEC EDGAR
| -$0.21 |
| -$0.36 |
| -$0.56 |
| -$0.73 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.